TY - JOUR AU - Jemal, A. AU - Murray, T. AU - Samuels, A. AU - Ghafoor, A. AU - Ward, E. AU - Thun, M. J. PY - 2003 DA - 2003// TI - Cancer statistics, 2003 JO - CA Cancer J Clin VL - 53 UR - https://doi.org/10.3322/canjclin.53.1.5 DO - 10.3322/canjclin.53.1.5 ID - Jemal2003 ER - TY - JOUR AU - Parkin, D. M. AU - Bray, F. AU - Ferlay, J. AU - Pisani, P. PY - 2005 DA - 2005// TI - Global cancer statistics, 2002 JO - CA Cancer J Clin VL - 55 UR - https://doi.org/10.3322/canjclin.55.2.74 DO - 10.3322/canjclin.55.2.74 ID - Parkin2005 ER - TY - JOUR AU - Grothey, A. AU - Sargent, D. AU - Goldberg, R. M. AU - Schmoll, H. J. PY - 2004 DA - 2004// TI - Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment JO - J Clin Oncol VL - 22 UR - https://doi.org/10.1200/JCO.2004.11.037 DO - 10.1200/JCO.2004.11.037 ID - Grothey2004 ER - TY - JOUR AU - Douillard, J. Y. AU - Cunningham, D. AU - Roth, A. D. AU - Navarro, M. AU - James, R. D. AU - Karasek, P. AU - Jandik, P. AU - Iveson, T. AU - Carmichael, J. AU - Alakl, M. AU - Gruia, G. AU - Awad, L. AU - Rougier, P. PY - 2000 DA - 2000// TI - Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial JO - Lancet VL - 355 UR - https://doi.org/10.1016/S0140-6736(00)02034-1 DO - 10.1016/S0140-6736(00)02034-1 ID - Douillard2000 ER - TY - JOUR AU - Tournigand, C. AU - Andre, T. AU - Achille, E. AU - Lledo, G. AU - Flesh, M. AU - Mery-Mignard, D. AU - Quinaux, E. AU - Couteau, C. AU - Buyse, M. AU - Ganem, G. AU - Landi, B. AU - Colin, P. AU - Louvet, C. AU - de, G. A. PY - 2004 DA - 2004// TI - FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study JO - J Clin Oncol VL - 22 UR - https://doi.org/10.1200/JCO.2004.05.113 DO - 10.1200/JCO.2004.05.113 ID - Tournigand2004 ER - TY - JOUR AU - Hurwitz, H. I. AU - Fehrenbacher, L. AU - Hainsworth, J. D. AU - Heim, W. AU - Berlin, J. AU - Holmgren, E. AU - Hambleton, J. AU - Novotny, W. F. AU - Kabbinavar, F. PY - 2005 DA - 2005// TI - Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer JO - J Clin Oncol VL - 23 UR - https://doi.org/10.1200/JCO.2005.10.017 DO - 10.1200/JCO.2005.10.017 ID - Hurwitz2005 ER - TY - JOUR AU - Kabbinavar, F. F. AU - Hambleton, J. AU - Mass, R. D. AU - Hurwitz, H. I. AU - Bergsland, E. AU - Sarkar, S. PY - 2005 DA - 2005// TI - Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer JO - J Clin Oncol VL - 23 UR - https://doi.org/10.1200/JCO.2005.00.232 DO - 10.1200/JCO.2005.00.232 ID - Kabbinavar2005 ER - TY - JOUR AU - Kabbinavar, F. F. AU - Schulz, J. AU - McCleod, M. AU - Patel, T. AU - Hamm, J. T. AU - Hecht, J. R. AU - Mass, R. AU - Perrou, B. AU - Nelson, B. AU - Novotny, W. F. PY - 2005 DA - 2005// TI - Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial JO - J Clin Oncol VL - 23 UR - https://doi.org/10.1200/JCO.2005.05.112 DO - 10.1200/JCO.2005.05.112 ID - Kabbinavar2005 ER - TY - JOUR AU - Hurwitz, H. AU - Fehrenbacher, L. AU - Novotny, W. AU - Cartwright, T. AU - Hainsworth, J. AU - Heim, W. AU - Berlin, J. AU - Baron, A. AU - Griffing, S. AU - Holmgren, E. AU - Ferrara, N. AU - Fyfe, G. AU - Rogers, B. AU - Ross, R. AU - Kabbinavar, F. PY - 2004 DA - 2004// TI - Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer JO - N Engl J Med VL - 350 UR - https://doi.org/10.1056/NEJMoa032691 DO - 10.1056/NEJMoa032691 ID - Hurwitz2004 ER - TY - JOUR AU - Goldberg, R. M. AU - Gill, S. PY - 2004 DA - 2004// TI - Recent phase III trials of fluorouracil, irinotecan, and oxaliplatin as chemotherapy for metastatic colorectal cancer JO - Cancer Chemother Pharmacol VL - 54 Suppl 1 ID - Goldberg2004 ER - TY - JOUR AU - Goldberg, R. M. AU - Sargent, D. J. AU - Morton, R. F. AU - Fuchs, C. S. AU - Ramanathan, R. K. AU - Williamson, S. K. AU - Findlay, B. P. AU - Pitot, H. C. AU - Alberts, S. PY - 2006 DA - 2006// TI - Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: a North American Intergroup Trial JO - J Clin Oncol VL - 24 UR - https://doi.org/10.1200/JCO.2006.06.1317 DO - 10.1200/JCO.2006.06.1317 ID - Goldberg2006 ER - TY - JOUR AU - Giantonio, B. J. AU - Catalano, P. J. AU - Meropol, N. J. PY - 2007 DA - 2007// TI - High dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: Results from the Eastern Cooperative Oncology Group (ECOG) study E3200. JO - J Clin Oncol VL - 25 UR - https://doi.org/10.1200/JCO.2006.09.6305 DO - 10.1200/JCO.2006.09.6305 ID - Giantonio2007 ER - TY - STD TI - National Cancer Institute: Common toxicity criteria, Version 2, 1999. 2006 ID - ref13 ER - TY - JOUR AU - Therasse, P. AU - Arbuck, S. G. AU - Eisenhauer, E. A. AU - Wanders, J. AU - Kaplan, R. S. AU - Rubinstein, L. AU - Verweij, J. AU - Van, G. M. AU - van Oosterom, A. T. AU - Christian, M. C. AU - Gwyther, S. G. PY - 2000 DA - 2000// TI - New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada JO - J Natl Cancer Inst VL - 92 UR - https://doi.org/10.1093/jnci/92.3.205 DO - 10.1093/jnci/92.3.205 ID - Therasse2000 ER - TY - JOUR AU - E.L., K. AU - P., M. PY - 1958 DA - 1958// TI - Non-parametric estimation from incomplete observations JO - J Am Stat Assoc VL - 53 UR - https://doi.org/10.1080/01621459.1958.10501452 DO - 10.1080/01621459.1958.10501452 ID - E.L.1958 ER - TY - BOOK AU - D.R., C. PY - 1970 DA - 1970// TI - The analysis of Biniary Data PB - London CY - Methnen ID - D.R.1970 ER - TY - JOUR AU - Kohne, C. H. AU - Cunningham, D. AU - Di, C. F. AU - Glimelius, B. AU - Blijham, G. AU - Aranda, E. AU - Scheithauer, W. AU - Rougier, P. AU - Palmer, M. AU - Wils, J. AU - Baron, B. AU - Pignatti, F. AU - Schoffski, P. AU - Micheel, S. AU - Hecker, H. PY - 2002 DA - 2002// TI - Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients JO - Ann Oncol VL - 13 UR - https://doi.org/10.1093/annonc/mdf034 DO - 10.1093/annonc/mdf034 ID - Kohne2002 ER - TY - JOUR AU - Hurwitz, H. AU - Kabbinavar, F. PY - 2005 DA - 2005// TI - Bevacizumab combined with standard fluoropyrimidine-based chemotherapy regimens to treat colorectal cancer JO - Oncology VL - 69 Suppl 3 UR - https://doi.org/10.1159/000088480 DO - 10.1159/000088480 ID - Hurwitz2005 ER - TY - JOUR AU - Emmanouilides, C. AU - Pegram, M. AU - Robinson, R. AU - Hecht, R. AU - Kabbinavar, F. AU - Isacoff, W. PY - 2004 DA - 2004// TI - Anti-VEGF antibody bevacizumab (Avastin) with 5FU/LV as third line treatment for colorectal cancer JO - Tech Coloproctol VL - 8 Suppl 1 UR - https://doi.org/10.1007/s10151-004-0110-4 DO - 10.1007/s10151-004-0110-4 ID - Emmanouilides2004 ER - TY - JOUR AU - Price, N. PY - 2004 DA - 2004// TI - Bevacizumab improves the efficacy of 5-fluorouracil/leucovorin in patients with advanced colorectal cancer JO - Clin Colorectal Cancer VL - 4 UR - https://doi.org/10.1016/S1533-0028(11)70106-2 DO - 10.1016/S1533-0028(11)70106-2 ID - Price2004 ER - TY - JOUR AU - Kabbinavar, F. AU - Hurwitz, H. I. AU - Fehrenbacher, L. AU - Meropol, N. J. AU - Novotny, W. F. AU - Lieberman, G. AU - Griffing, S. AU - Bergsland, E. PY - 2003 DA - 2003// TI - Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer JO - J Clin Oncol VL - 21 UR - https://doi.org/10.1200/JCO.2003.10.066 DO - 10.1200/JCO.2003.10.066 ID - Kabbinavar2003 ER - TY - CHAP AU - Hochster, H. S. AU - Hart, L. L. AU - Ramanathan, R. K. AU - Hainsworth, E. E. AU - Childs, B. H. PY - 2006 DA - 2006// TI - Safety and efficacy of oxaliplatin/fluoropyrimidines regimens with or without bavacizumab as first-line treatment of metastatic colorectal cancer(mCRC): Final analysis of the TREE-study BT - Proc ASCO ID - Hochster2006 ER - TY - CHAP AU - Saltz, L. B. AU - Clarke, E. AU - Diaz-Rubio, E. AU - Scheithauer, A. AU - Figer, A. AU - Wong, R. AU - Koski, S. AU - Lichinitser, M. AU - Yang, T. AU - Cassidy, J. PY - 2007 DA - 2007// TI - First efficacy and safety results from XELOX-1/NO16966, a randomised 2x2 factorial phase III trial of XELOX vs FOLFOX4 + bevacizumab or placebo in first-line metastatic colorectal cancer BT - Proc GASTROINTESTINAL CANCER SYMPOSIUM ID - Saltz2007 ER - TY - STD TI - The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/7/91/prepub UR - http://www.biomedcentral.com/1471-2407/7/91/prepub ID - ref24 ER -